Investor Relations
Nasdaq: CNSP
| CNS Pharmaceuticals |
Periodic Reports
News Releases
Events
Corporate Presentation
Stay Updated
Firm
Analyst
Jason McCarthy, PhD
Maxim Group
James Molloy
A.G.P. / Alliance Global Partners
CNS Pharmaceuticals, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding CNS Pharmaceuticals, Inc.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of CNS Pharmaceuticals, Inc. or its management. CNS Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
CNS Pharmaceuticals is a biotechnology company focused on building a pipeline of innovative therapies for serious diseases in neurology and oncology. Leveraging an experienced leadership team and a disciplined strategy to identify high-value therapeutic opportunities, the Company is working to develop a differentiated portfolio of treatments that address significant unmet medical needs. CNS Pharmaceuticals is committed to advancing novel therapies that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.